Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: The mutations and salvage study

被引:12
作者
Gianotti, N
Mondino, V
Rossi, MC
Chiesa, E
Mezzaroma, I
Ladisa, N
Guaraldi, G
Torti, C
Tarquini, P
Castelli, P
Di Carlo, A
Boeri, E
Keulen, W
Mc Kenna, P
Lazzarin, A
机构
[1] Univ Vita Salute San Raffaele, Clin Malattie Infett, Milan, Italy
[2] Osped L Sacco, Clin Malattie Infett, Milan, Italy
[3] Diagnost & Ric San Raffaele, Milan, Italy
[4] Osped Riuniti Pallanza, Div Malattie Infett, Verbania, Italy
[5] Osped Ca Foncello, Div Malattie Infett, Treviso, Italy
[6] Univ Roma La Sapienza, Dipartimento Med Clin, Rome, Italy
[7] Ist Ricovero & Cura & Carattere Sci Demosifilopat, Unita Operat AIDS Rome 71, Rome, Italy
[8] Policlin Bari, Clin Malattie Infett, Bari, Italy
[9] Univ Modena, Clin Malattie Infett & Trop, I-41100 Modena, Italy
[10] Spedali Civil Brescia, Clin Malattie Infett & Trop, I-25125 Brescia, Italy
[11] Osped G Mazzini, Unita Operat Malattie Infett, Teramo, Italy
[12] Osped Macerata, Reparto Malattie Infett, Macerata, Italy
[13] Virol Educ, Utrecht, Netherlands
[14] Virco, Mechelen, Belgium
关键词
D O I
10.1086/503568
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. There is still considerable uncertainty as to the best algorithm for interpreting humanimmunodeficiency virus (HIV) genotyping results. Methods. A total of 318 subjects with HIV RNA levels of > 1000 copies/mL were enrolled in 41 centers throughout Italy from 2001 through 2003, stratified on the basis of their drug history, randomized (1:1) to 2 arms to have their treatments modified on the basis of the results of HIV genotyping (as interpreted by virtual phenotype analysis or with use of a rule-based interpretation system), and followed up for 48 weeks. At least 1 nucleoside reverse-transcriptase inhibitor and 1 protease inhibitor had to be included in any new regimen; nonnucleoside reverse-transcriptase inhibitor naive patients were also prescribed a nonnucleoside reverse-transcriptase inhibitor. Only drugs licensed in Italy were allowed. The primary end point was a decrease in HIV RNA level to < 400 copies/mL by week 12 according to on-treatment analysis. Results. The mean (+/- standard deviation) values at baseline were as follows: HIV RNA level, log(10) copies/mL; CD4(+) T lymphocyte count, cells/mu L; reverse-transcriptase mutations,4.8 +/- 2.9; and protease mutationa, mutations, 2.8 +/- 2.5. There were 133 patients (41.8%) who were nonnucleoside reverse-transcriptase inhibitor naive and protease inhibitor experienced, 63 patients (19.8%) who were nonnucleoside reverse- transcriptase inhibitor experienced and protease inhibitor naive, and 122 patients (38.4%) who were 3-class experienced. A total of 192 patients completed 12 weeks of the treatment regimen assigned at baseline; at 12 weeks, 66.3% of patients in the virtual phenotype arm and 71.3% of patients in the rule-based interpretation arm had HIV RNA levels of ! 400 copies/ mL (P = .46). No statistically significant difference between arms was observed by intention-to-treat analysis. Conclusion. Both the virtual phenotype and rule-based interpretation methods of HIV genotyping can guide the selection of effective antiretroviral drugs for a salvage regimen.
引用
收藏
页码:1470 / 1480
页数:11
相关论文
共 13 条
  • [1] A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
    Baxter, JD
    Mayers, DL
    Wentworth, DN
    Neaton, JD
    Hoover, ML
    Winters, MA
    Mannheimer, SB
    Thompson, MA
    Abrams, DI
    Brizz, BJ
    Ioannidis, JPA
    Merigan, TC
    [J]. AIDS, 2000, 14 (09) : F83 - F93
  • [2] Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA)
    Cingolani, A
    Antinori, A
    Rizzo, MG
    Murri, R
    Ammassari, A
    Baldini, F
    Di Giambenedetto, S
    Cauda, R
    De Luca, A
    [J]. AIDS, 2002, 16 (03) : 369 - 379
  • [3] A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
    Cohen, CJ
    Hunt, S
    Sension, M
    Farthing, C
    Conant, M
    Jacobson, S
    Nadler, J
    Verbiest, W
    Hertogs, K
    Ames, M
    Rinehart, AR
    Graham, NM
    [J]. AIDS, 2002, 16 (04) : 579 - 588
  • [4] Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type I drug resistance
    De Luca, A
    Cingolani, A
    Di Giambenedetto, S
    Trotta, MP
    Baldini, F
    Rizzo, MG
    Bertoli, A
    Liuzzi, G
    Narciso, P
    Murri, R
    Antmassari, A
    Perno, CF
    Antinori, A
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (12) : 1934 - 1943
  • [5] Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial
    Durant, J
    Clevenbergh, P
    Halfon, P
    Delgiudice, P
    Porsin, S
    Simonet, P
    Montagne, N
    Boucher, CAB
    Schapiro, JM
    Dellamonica, P
    [J]. LANCET, 1999, 353 (9171) : 2195 - 2199
  • [6] World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing
    Harrigan, PR
    Montaner, JSG
    Wegner, SA
    Verbiest, W
    Miller, V
    Wood, R
    Larder, BA
    [J]. AIDS, 2001, 15 (13) : 1671 - 1677
  • [7] Haubrich RH, 2005, AIDS, V19, P295
  • [8] Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure:: a randomized trial
    Meynard, JL
    Vray, M
    Morand-Joubert, L
    Race, E
    Descamps, D
    Peytavin, G
    Matheron, S
    Lamotte, C
    Guiramand, S
    Costagliola, D
    Brun-Vézinet, F
    Clavel, F
    Girard, PM
    [J]. AIDS, 2002, 16 (05) : 727 - 736
  • [9] Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients
    Monforte, AD
    Lepri, AC
    Rezza, G
    Pezzotti, P
    Antinori, A
    Phillips, AN
    Angarano, G
    Colangeli, V
    De Luca, A
    Ippolito, G
    Caggese, L
    Soscia, F
    Filice, G
    Gritti, F
    Narciso, P
    Tirelli, U
    Moroni, M
    [J]. AIDS, 2000, 14 (05) : 499 - 507
  • [10] Limited benefit of antiretrovial resistance testing in treatment-experienced patients: a meta-analysis
    Panidou, ET
    Trikalinos, TA
    Ioannidis, JPA
    [J]. AIDS, 2004, 18 (16) : 2153 - 2161